Perimeter Medical Imaging AI (TSE:PINK)
:PINK
Top Page
Perimeter Medical Imaging AI
(PINK)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.24
▼(-28.79% Downside)
Action:DowngradedDate:01/29/26
The score is held down primarily by weak financial quality (persistent losses and negative operating/free cash flow) despite solid gross margins and revenue growth, and by bearish technicals with the stock trading below key moving averages. Valuation adds limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
Low Leverage
Very low debt provides durable financial flexibility: it lowers solvency risk, preserves borrowing capacity for capital expenditures or clinical commercialization, and reduces fixed interest costs, enabling the company to prioritize R&D and go-to-market investments over urgent deleveraging.
Negative Factors
Negative Profitability
Persistent negative net and EBIT margins indicate the business is not yet operationally profitable. Without sustained operating leverage or cost reductions, continued losses can impair reinvestment capacity, delay returns to shareholders, and require recurring financing that dilutes long-term stakeholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt provides durable financial flexibility: it lowers solvency risk, preserves borrowing capacity for capital expenditures or clinical commercialization, and reduces fixed interest costs, enabling the company to prioritize R&D and go-to-market investments over urgent deleveraging.
Read all positive factors
Perimeter Medical Imaging AI (PINK) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$41.62M
Dividend YieldN/A
Average Volume (3M)55.39K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth209.29%
EPS Growth35.38%
CountryCA
Employees65
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding126,112,560
10 Day Avg. Volume68,307
30 Day Avg. Volume55,392
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.60
Price to Sales (P/S)32.11
P/FCF Ratio-1.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.00Price Target Upside809.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)C$6.86M
Perimeter Medical Imaging AI Business Overview & Revenue Model
Company Description
Perimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The co...
How the Company Makes Money
Perimeter Medical Imaging AI generates revenue primarily through the sales of its imaging systems and associated consumables to hospitals and surgical centers. The company also earns income from ongoing service agreements and maintenance contracts...
Perimeter Medical Imaging AI Earnings Call Summary
Earnings Call Date:Aug 26, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Jun 02, 2026
Earnings Call Sentiment Neutral
The earnings call reflects significant positive developments, such as strong revenue growth, positive trial results, and increased product utilization. However, challenges remain with an increased net loss, limited cash reserves, and constraints due to a small commercial team. While the highlights are impressive, the lowlights present notable hurdles that need addressing.Positive Updates
Significant Revenue Growth
The company recorded revenue of $506,000 for Q2 2025, representing a 105% increase over Q2 2024. Additionally, revenue for the first six months of 2025 was 25% higher than the total for all of 2024.
Negative Updates
Net Loss Increase
Second quarter 2025 net loss was $3.9 million compared to $3.2 million in the same period in 2024.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Revenue Growth
The company recorded revenue of $506,000 for Q2 2025, representing a 105% increase over Q2 2024. Additionally, revenue for the first six months of 2025 was 25% higher than the total for all of 2024.
Read all positive updates
Company Guidance
During the Perimeter Medical Second Quarter 2025 Conference Call, key financial and operational metrics were highlighted. The company recorded $506,000 in revenue for the quarter ending June 30, 2025, marking a 105% increase from Q2 2024. The gross margin remained consistent at 70%. Operating expenses decreased by 22% to $4.3 million compared to the same period in 2024. Despite these improvements, Perimeter reported a net loss of $3.9 million. The company had cash and cash equivalents of approximately $1.4 million, excluding $1.6 million from a recent offering and a $745,000 grant receivable. The CEO, Adrian Mendes, emphasized ongoing efforts to commercialize the FDA-cleared S-Series OCT system, with a 25% revenue increase in the first half of 2025 compared to all of 2024. Utilization rates showed significant growth of 93% year-over-year and 35% sequentially. The company is awaiting FDA approval for its next-generation B-Series device, expected by late Q4 2025 or Q1 2026, and is preparing for an aggressive rollout. Cost-saving measures are projected to reduce operating expenses by approximately 30% starting in Q3.Perimeter Medical Imaging AI Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09M | 846.19K | 403.53K | 132.77K | 11.34K | 0.00 |
| Gross Profit | 1.07M | 535.11K | 206.42K | 100.63K | 5.04K | -47.57K |
| EBITDA | -13.49M | -12.64M | -18.13M | -11.72M | -15.95M | -6.11M |
| Net Income | -15.37M | -13.39M | -18.94M | -3.59M | -16.76M | -8.00M |
Balance Sheet | ||||||
| Total Assets | 8.33M | 14.33M | 27.09M | 34.60M | 9.98M | 13.16M |
| Cash, Cash Equivalents and Short-Term Investments | 2.35M | 6.18M | 18.43M | 28.44M | 5.14M | 11.70M |
| Total Debt | 101.75K | 137.48K | 192.89K | 325.68K | 441.17K | 400.81K |
| Total Liabilities | 3.49M | 3.87M | 7.10M | 8.49M | 2.56M | 2.40M |
| Stockholders Equity | 4.84M | 10.45M | 15.06M | 26.11M | 7.42M | 10.76M |
Cash Flow | ||||||
| Free Cash Flow | -12.78M | -16.90M | -15.17M | -13.86M | -16.03M | -8.26M |
| Operating Cash Flow | -10.99M | -14.72M | -14.70M | -11.87M | -13.91M | -8.26M |
| Investing Cash Flow | -1.71M | -1.90M | 206.01K | -1.75M | -1.45M | 7.24M |
| Financing Cash Flow | 4.77M | 8.58M | 234.47K | 40.28M | 10.06M | 9.84M |
Perimeter Medical Imaging AI Technical Analysis
Negative
0.33
Price Trends
0.36
Negative
0.32
Positive
0.28
Positive
Market Momentum
>-0.01
Positive
39.20
Neutral
4.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.36, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.20 is Neutral, neither overbought nor oversold. The STOCH value of 4.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PINK.
Perimeter Medical Imaging AI Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | C$21.58M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
46 Neutral | C$21.31M | -29.60 | -31.12% | ― | 9.71% | -118.02% | |
46 Neutral | C$69.41M | -11.76 | -269.41% | ― | 1.46% | 6.91% | |
42 Neutral | C$41.62M | -1.50 | -220.14% | ― | 209.29% | 35.38% |
* General Sector Average
TSE:PINK
Perimeter Medical Imaging AI
0.33
-0.10
-24.14%
TSE:ASG
Aurora Spine
0.27
-0.05
-14.69%
TSE:IME
Imagin Medical
0.02
0.00
0.00%
TSE:TLT
Theralase Technologies
0.27
0.10
58.82%
TSE:VPT
VentriPoint Diagnostics
0.12
-0.03
-17.86%
Perimeter Medical Imaging AI Corporate Events
Business Operations and StrategyProduct-Related Announcements
Perimeter Medical Imaging AI Strikes Systemwide Deployment Deal with Intermountain Health
Positive
Jan 8, 2026
Perimeter Medical Imaging AI has entered a systemwide agreement with Intermountain Health that allows deployment of its S-Series OCT intraoperative imaging technology across the nonprofit health system’s 34 hospitals and 400 clinics in the I...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Perimeter Medical Imaging AI Shareholders Back Board Slate and Expanded Incentive Plan
Positive
Dec 29, 2025
Perimeter Medical Imaging AI reported that shareholders approved all items at its annual general and special meeting, including the election of four directors to its board after the post-meeting resignation of Michelle Caron for personal reasons, ...
Business Operations and StrategyPrivate Placements and Financing
Perimeter Medical Imaging AI Secures C$3.6 Million to Boost Commercialization Efforts
Positive
Dec 9, 2025
Perimeter Medical Imaging AI has successfully closed a C$3.6 million non-brokered private placement, led by insiders including CEO Adrian Mendes. The capital raised will be used to accelerate the commercialization of the current S-Series device an...
Business Operations and StrategyProduct-Related Announcements
Perimeter’s S-Series OCT Technology Adopted by HCA HealthONE Rose in Colorado
Positive
Nov 17, 2025
Perimeter Medical Imaging AI announced that HCA HealthONE Rose in Colorado is the first in the state to adopt its S-Series OCT imaging technology for surgical use. This adoption marks a significant expansion of Perimeter’s commercial footpri...
Business Operations and StrategyFinancial Disclosures
Perimeter Medical Imaging AI Reports Robust Q3 2025 Financial Results Amidst Growing Market Traction
Positive
Nov 12, 2025
Perimeter Medical Imaging AI reported strong financial results for Q3 2025, with significant revenue growth and reduced operating expenses. The company’s S-Series device is gaining traction in top medical centers, contributing to a 157% year...
Financial Disclosures
Perimeter Medical Imaging AI to Announce Q3 2025 Financial Results
Neutral
Nov 5, 2025
Perimeter Medical Imaging AI announced it will release its third quarter 2025 financial results on November 12, 2025, followed by a conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it prov...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.